Tags

Type your tag names separated by a space and hit enter

The Rationale for Potential Pharmacotherapy of COVID-19.
Pharmaceuticals (Basel). 2020 May 14; 13(5)P

Abstract

On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first appeared in Wuhan, China in December 2019 and spread rapidly all over the world. COVID-19 is being increasingly investigated through virology, epidemiology, and clinical management strategies. There is currently no established consensus on the standard of care in the pharmacological treatment of COVID-19 patients. However, certain medications suggested for other diseases have been shown to be potentially effective for treating this infection, though there has yet to be clear evidence. Therapies include new agents that are currently tested in several clinical trials, in addition to other medications that have been repurposed as antiviral and immune-modulating therapies. Previous high-morbidity human coronavirus epidemics such as the 2003 SARS-CoV and the 2012 Middle East respiratory syndrome coronavirus (MERS-CoV) prompted the identification of compounds that could theoretically be active against the emerging coronavirus SARS-CoV-2. Moreover, advances in molecular biology techniques and computational analysis have allowed for the better recognition of the virus structure and the quicker screening of chemical libraries to suggest potential therapies. This review aims to summarize rationalized pharmacotherapy considerations in COVID-19 patients in order to serve as a tool for health care professionals at the forefront of clinical care during this pandemic. All the reviewed therapies require either additional drug development or randomized large-scale clinical trials to be justified for clinical use.

Links

PMC Free PDF

Authors+Show Affiliations

Saber-Ayad M
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAE. College of Medicine, Cairo University, Cairo 12613, Egypt.
Saleh MA
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAE. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Abu-Gharbieh E
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAE.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32423024

Citation

Saber-Ayad, Maha, et al. "The Rationale for Potential Pharmacotherapy of COVID-19." Pharmaceuticals (Basel, Switzerland), vol. 13, no. 5, 2020.
Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals (Basel). 2020;13(5).
Saber-Ayad, M., Saleh, M. A., & Abu-Gharbieh, E. (2020). The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals (Basel, Switzerland), 13(5). https://doi.org/10.3390/ph13050096
Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals (Basel). 2020 May 14;13(5) PubMed PMID: 32423024.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Rationale for Potential Pharmacotherapy of COVID-19. AU - Saber-Ayad,Maha, AU - Saleh,Mohamed A, AU - Abu-Gharbieh,Eman, Y1 - 2020/05/14/ PY - 2020/04/22/received PY - 2020/05/09/revised PY - 2020/05/11/accepted PY - 2020/5/20/entrez PY - 2020/5/20/pubmed PY - 2020/5/20/medline KW - ACE2 KW - COVID-19 KW - SARS-CoV-2 KW - TMPRSS2 KW - baricitinib KW - chloroquine KW - favipiravir KW - interferons KW - lopinavir KW - remdesivir JF - Pharmaceuticals (Basel, Switzerland) JO - Pharmaceuticals (Basel) VL - 13 IS - 5 N2 - On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first appeared in Wuhan, China in December 2019 and spread rapidly all over the world. COVID-19 is being increasingly investigated through virology, epidemiology, and clinical management strategies. There is currently no established consensus on the standard of care in the pharmacological treatment of COVID-19 patients. However, certain medications suggested for other diseases have been shown to be potentially effective for treating this infection, though there has yet to be clear evidence. Therapies include new agents that are currently tested in several clinical trials, in addition to other medications that have been repurposed as antiviral and immune-modulating therapies. Previous high-morbidity human coronavirus epidemics such as the 2003 SARS-CoV and the 2012 Middle East respiratory syndrome coronavirus (MERS-CoV) prompted the identification of compounds that could theoretically be active against the emerging coronavirus SARS-CoV-2. Moreover, advances in molecular biology techniques and computational analysis have allowed for the better recognition of the virus structure and the quicker screening of chemical libraries to suggest potential therapies. This review aims to summarize rationalized pharmacotherapy considerations in COVID-19 patients in order to serve as a tool for health care professionals at the forefront of clinical care during this pandemic. All the reviewed therapies require either additional drug development or randomized large-scale clinical trials to be justified for clinical use. SN - 1424-8247 UR - https://www.unboundmedicine.com/medline/citation/32423024/The_Rationale_for_Potential_Pharmacotherapy_of_COVID_19_ DB - PRIME DP - Unbound Medicine ER -